Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Novel assays to investigate the mechanisms of latent infection with HIV-2.
Lu MD, Telwatte S, Kumar N, Ferreira F, Martin HA, Kadiyala GN, Wedrychowski A, Moron-Lopez S, Chen TH, Goecker EA, Coombs RW, Lu CM, Wong JK, Tsibris A, Yukl SA. Lu MD, et al. Among authors: tsibris a. PLoS One. 2022 Apr 27;17(4):e0267402. doi: 10.1371/journal.pone.0267402. eCollection 2022. PLoS One. 2022. PMID: 35476802 Free PMC article.
HIV-1 proviral landscape characterization varies by pipeline analysis.
Ferreira FA, He Q, Banning S, Roberts-Sano O, Wilkins O, Kuritzkes DR, Tsibris A. Ferreira FA, et al. Among authors: tsibris a. J Int AIDS Soc. 2021 Jul;24(7):e25725. doi: 10.1002/jia2.25725. J Int AIDS Soc. 2021. PMID: 34235860 Free PMC article.
Vicriviroc resistance decay and relative replicative fitness in HIV-1 clinical isolates under sequential drug selection pressures.
Tsibris AM, Hu Z, Paredes R, Leopold KE, Putcharoen O, Schure AL, Mazur N, Coakley E, Su Z, Gulick RM, Kuritzkes DR. Tsibris AM, et al. J Virol. 2012 Jun;86(12):6416-26. doi: 10.1128/JVI.00286-12. Epub 2012 Apr 4. J Virol. 2012. PMID: 22491471 Free PMC article. Clinical Trial.
We previously described an HIV-1-infected individual who developed resistance to vicriviroc (VCV), an investigational CCR5 antagonist, during 28 weeks of therapy (Tsibris AM et al., J. Virol. 82:8210-8214, 2008). To investigate the decay of VCV resistance mutations, a …
We previously described an HIV-1-infected individual who developed resistance to vicriviroc (VCV), an investigational CCR5 antagonist, durin …
Barriers to a cure for HIV in women.
Gianella S, Tsibris A, Barr L, Godfrey C. Gianella S, et al. Among authors: tsibris a. J Int AIDS Soc. 2016 Feb 18;19(1):20706. doi: 10.7448/IAS.19.1.20706. eCollection 2016. J Int AIDS Soc. 2016. PMID: 26900031 Free PMC article. Review.
Anti-apoptotic Protein BIRC5 Maintains Survival of HIV-1-Infected CD4+ T Cells.
Kuo HH, Ahmad R, Lee GQ, Gao C, Chen HR, Ouyang Z, Szucs MJ, Kim D, Tsibris A, Chun TW, Battivelli E, Verdin E, Rosenberg ES, Carr SA, Yu XG, Lichterfeld M. Kuo HH, et al. Among authors: tsibris a. Immunity. 2018 Jun 19;48(6):1183-1194.e5. doi: 10.1016/j.immuni.2018.04.004. Epub 2018 May 22. Immunity. 2018. PMID: 29802019 Free PMC article.
48 results